These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 7718899)

  • 1. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM).
    Devergie A; Blaise D; Attal M; Tigaud JD; Jouet JP; Vernant JP; Bordigoni P; Ifrah N; Dauriac C; Cahn JY
    Blood; 1995 Apr; 85(8):2263-8. PubMed ID: 7718899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic bone marrow transplantation for chronic myeloid leukemia: a retrospective study of busulfan-cytoxan versus total body irradiation-cytoxan as preparative regimen in Koreans.
    Kim I; Park S; Kim BK; Chang HM; Bang SM; Byun JH; Kim DJ; Min WS; Kim HJ; Kim CC
    Clin Transplant; 2001 Jun; 15(3):167-72. PubMed ID: 11389706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.
    Clift RA; Buckner CD; Thomas ED; Bensinger WI; Bowden R; Bryant E; Deeg HJ; Doney KC; Fisher LD; Hansen JA
    Blood; 1994 Sep; 84(6):2036-43. PubMed ID: 8081005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.
    Blume KG; Kopecky KJ; Henslee-Downey JP; Forman SJ; Stiff PJ; LeMaistre CF; Appelbaum FR
    Blood; 1993 Apr; 81(8):2187-93. PubMed ID: 8471778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Ringdén O; Labopin M; Tura S; Arcese W; Iriondo A; Zittoun R; Sierra J; Gorin NC
    Br J Haematol; 1996 Jun; 93(3):637-45. PubMed ID: 8652385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up.
    Aschan J; Carlens S; Hägglund H; Klaesson S; Mattsson J; Remberger M
    Clin Transplant; 1999 Dec; 13(6):512-9. PubMed ID: 10617242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Busulfan and cyclophosphamide versus cyclophosphamide and total body irradiation for marrow transplantation in chronic myelogenous leukemia--a review.
    Santos GW
    Leuk Lymphoma; 1993; 11 Suppl 1():201-4. PubMed ID: 8251896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
    Socié G; Clift RA; Blaise D; Devergie A; Ringden O; Martin PJ; Remberger M; Deeg HJ; Ruutu T; Michallet M; Sullivan KM; Chevret S
    Blood; 2001 Dec; 98(13):3569-74. PubMed ID: 11739158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia.
    Dusenbery KE; Daniels KA; McClure JS; McGlave PB; Ramsay NK; Blazar BR; Neglia JP; Kersey JH; Woods WG
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):119-28. PubMed ID: 7995742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.
    Copelan EA; Avalos BR; Ahn KW; Zhu X; Gale RP; Grunwald MR; Hamadani M; Hamilton BK; Hale GA; Marks DI; Waller EK; Savani BN; Costa LJ; Ramanathan M; Cahn JY; Khoury HJ; Weisdorf DJ; Inamoto Y; Kamble RT; Schouten HC; Wirk B; Litzow MR; Aljurf MD; van Besien KW; Ustun C; Bolwell BJ; Bredeson CN; Fasan O; Ghosh N; Horowitz MM; Arora M; Szer J; Loren AW; Alyea EP; Cortes J; Maziarz RT; Kalaycio ME; Saber W
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):552-8. PubMed ID: 25528388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
    Demirer T; Buckner CD; Appelbaum FR; Lambert K; Bensinger WI; Clift R; Storb R; Slattery JT
    Bone Marrow Transplant; 1996 Mar; 17(3):341-6. PubMed ID: 8704684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia.
    Uberti JP; Agovi MA; Tarima S; Haagenson M; Gandham S; Anasetti C; Baker KS; Bolwell BJ; Bornhauser M; Chan KW; Copelan E; Davies SM; Finke J; Hale GA; Kollman C; McCarthy PL; Ratanatharathorn V; Ringdén O; Weisdorf DJ; Rizzo JD
    Bone Marrow Transplant; 2011 Jan; 46(1):34-43. PubMed ID: 20400989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
    Petersen FB; Buckner CD; Appelbaum FR; Clift RA; Sanders JE; Bensinger WI; Storb R; Witherspoon RP; Sullivan KM; Bearman SI
    Bone Marrow Transplant; 1989 Nov; 4(6):617-23. PubMed ID: 2684307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.
    Anderson JE; Appelbaum FR; Schoch G; Gooley T; Anasetti C; Bensinger WI; Bryant E; Buckner CD; Chauncey T; Clift RA
    J Clin Oncol; 1996 Jan; 14(1):220-6. PubMed ID: 8558201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide.
    Hartsell WF; Czyzewski EA; Ghalie R; Kaizer H
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):69-73. PubMed ID: 7536723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
    Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
    J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous bone marrow transplantation in acute myeloid leukemia: the University of Minnesota experience.
    Dusenbery KE; Steinbuch M; McGlave PB; Ramsay NK; Blazar BR; Neglia JP; Litz C; Kersey JH; Woods WG
    Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):335-43. PubMed ID: 8892457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.